Experimental evidence suggests a stimulatory effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on both platelets and coagulation. RhG-CSF is increasingly used to stimulate healthy volunteer donors for blood stem cell mobilization. We therefore assessed 25 healthy donors receiving rhG-CSF for changes in in vitro bleeding test (IVBT), coagulation parameters and cerebral microembolism by transcranial Doppler (TCD) ultrasound. A significant shortening of IVBT was found on day 4 of rhG-CSF administration together with increased levels of fibrinogen and factor VIII and reduced activities of protein C and protein S. Although these changes are quite small it is possible that they may lead to a hypercoagulable state especially in donors with other risk factors for thromboembolism. However, TCD examination failed to detect any signs of microembolism. We therefore conclude that rhG-CSF leads to significant changes in coagulation parameters, but has no effect on TCD detectable microembolism as a stroke risk factor. However donors receiving rhG-CSF should be examined carefully to detect pre-existing changes in the coagulation system and we would like to suggest a routine thrombophilia screen. Keywords: in vitro bleeding test; blood coagulation; recombinant human granulocyte colony-stimulating factor; transcranial Doppler ultrasound In the context of autologous and allogeneic stem cell transplantation rhG-CSF is routinely used as a growth factor to mobilize peripheral blood stem cells.
In the context of autologous and allogeneic stem cell transplantation rhG-CSF is routinely used as a growth factor to mobilize peripheral blood stem cells. 1, 2 In patients with normal bone marrow function this leads to a significant increase of peripheral leukocyte counts, so that rheological changes and disturbances of blood flow are to be anticipated. To date, we have noted thrombotic complications of central venous lines in two out of 20 patients under rhG-CSF administration. Moreover, in vitro tests demonstrated an activation of platelets and the coagulation system. 3, 4 As a growing number of healthy donors receive rhG-CSF for stem cell mobilization in our institution, we were interested Correspondence: D Söhngen, Department I of Internal Medicine, University of Köln, Joseph-Stelzmann-Str. 9, D-50924 Köln, Germany Received 7 April 1998; accepted 21 July 1998 to examine whether a very sensitive platelet function test (Thrombostat 4000, VDG, Seeon) would detect platelet activation and whether an activation of the coagulation system could be found. 5, 6 Finally, we used a non-invasive transcranial Doppler ultrasound examination to search for cellular aggregates as a marker of microembolism in the arterial circulation.
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Donors and methods
Donors
Twenty-five healthy donors (10 male, 15 female) received recombinant human G-CSF (Filgrastim, Amgen, Munich, Germany) at a daily dose of 12.5 g/kg subcutaneously for 5 days prior to allogeneic stem cell collection. Median age was 42 years with a range of 18-56 years. Ethical approval was obtained for the study and informed consent from all donors.
Platelet function test
For an in vitro bleeding test (IVBT, Thrombostat 4000, VDG, Seeon) in five donors blood samples were taken before, during (day 4, before stem cell collection) and 10 days after the end of rhG-CSF administration. Blood was mixed with citrate (1/10 v/v) and autologous component blood with 5000, 10 000 and 50 000 leukocytes/l was generated while keeping the haematocrit and platelets constant at 40% and 200 000/l, respectively. A collagen-coated type-I cellulose-acetate filter with a Teflon capillary (diameter 200 m, length 16 mm, aperture 120 m) was used with a constant pressure of 40 mbar. Stimulation was induced with 40 l of a 10 mm ADP-solution.
Coagulation tests
Blood was taken with citrate (1/10 v/v) in 10 donors before and during rhG-CSF administration on day 4 before stem cell collection. The following parameters were determined (in duplicate): prothrombin time, aPTT, factor VIII, protein S and protein C were measured on the Fibrintimer A (BFA) and Behring Coagulation Timer (BCT) (Behring, Marburg, Germany). Antithrombin III and plasminogen activity were measured with chromogenic assays (Hitachi 704 Boehringer, Mannheim, Germany), activated protein C-mediated inactivation (APC-resistance test) with Coatest APC resistance (Chromogenix, Mölndal, Sweden) and d-dimer test with NycoCard d-Dimer (Immuno, Heidelberg, Germany).
Transcranial Doppler ultrasound
Ten donors received long-term transcranial Doppler (TCD) signal recording of the middle cerebral artery for at least 30 min as described elsewhere, before and 4 days after beginning rhG-CSF administration before stem cell collection. The audible TCD analog output signal of the 2 MHz pulsed-waved probe (Multidop, DWL, Sipplingen, Germany) was recorded digitally on tape for further offline analyses and blinded rating using interobserver based rating criteria. 7, 8 
Statistical analysis
The Wilcoxon test for dependent samples was used. A twosided probability of Ͻ0.05 was considered significant.
Results
In all donors rhG-CSF induced a marked increase in leukocytes without significant changes in haemoglobin or platelet counts ( Table 1) . None of the 10 donors experienced thromboembolic complications either before or after rhG-CSF stimulation. Twenty-one donors noted moderate bone pain which was easily controlled by paracetamol.
RhG-CSF led to a significant reduction of bleeding time in the IVBT, the effect being more pronounced with lower leukocyte counts. Ten days after withdrawal of rhG-CSF the IVBT results went back to normal (Figure 1) .
During rhG-CSF administration changes in several coagulation parameters were found, indicating a state of hypercoagulation: levels of factor VIII and fibrinogen were significantly elevated whereas the activities of protein C and protein S were significantly reduced ( Table 2) .
None of 10 donors examined had evidence of cerebral microembolism as assessed by TCD (data not shown).
Discussion
RhG-CSF is increasingly used to mobilize stem cells in normal volunteer donors. In this setting safety issues are Table 1 Changes of leukocytes, haemoglobin and platelets in normal subjects prior to and 4 days after receiving rhG-CSF at 12.5 g/kg/day s. absolutely paramount. As we and others have found evidence for an activation of platelets and coagulation factors in patients receiving rhG-CSF, we assessed those parameters in normal donors given rhG-CSF. [9] [10] [11] [12] [13] [14] In fact, a significant reduction of the closure time in the in vitro bleeding test with rhG-CSF was found, together with increased levels of fibrinogen and factor VIII and reduced activity of protein C and protein S. Although these changes are quite small it seems likely that these changes may lead to a hypercoagulable state especially in donors with other risk factors for thromboembolism. However, these changes did not lead to any evidence of subclinical (or clinical) arterial microembolism as measured by the TCD. Several studies provide evidence that TCD detectable microembolic signals indicate a risk factor for cerebral ischemia. [15] [16] [17] Although the nature of the detected signals cannot be clearly identified, eg which aggregates of blood cells generate the signal, the method seems to be sensitive for blood inhomogeneity. The fact that after stimulation donors presented signs of hypercoagulation but no microembolism is compatible with the known clinical low incidence of ischemic morbidity. The clinical significance of a shortening of IVBT in special clinical situations is not quite clear. However, this method is highly sensitive in detecting deficiency of von Willebrand factor and congenital or acquired thrombocyte disorders (eg by acetylsalicylic acid). 18 To date, there are no comprehensive trials which predict or correlate IVBT with platelet activation or thrombotic risks. Nevertheless, according to preliminary clinical results, a shortening of IVBT indicated by a shorter closure time in patients with risk for stroke and cardiac disease may be the first indication that this method is not only sensitive for decreased platelet function and a higher bleeding risk but may be also sensitive to an increased thrombotic risk. 19, 20 Finally, the finding that the shortening of the closure time in our IVBT was more pronounced in tests with lower leukocyte count may partially be explained by improved rheology in the modified test arrangement.
A large number of donors have received rhG-CSF so far and to our knowledge no case of rhG-CSF-related thromboembolism has been reported. On the contrary, thromboembolism or a hypercoagulable state was often found in patients with malignant tumours receiving rhG-CSF. However, our data clearly show a rhG-CSF-dependent modulation of coagulation parameters which may become clinically relevant in donors with an a priori increased risk of thromboembolism. Therefore, patients and donors at risk * * 120 s 80 s 5000/ l 10 000/ l 50 000/ l prior to rhG-CSF 4 days during rhG-CSF 10 days after rhG-CSF * * * * * * of thrombosis or hypercoagulable state should be followed carefully after rhG-CSF administration. It may serve as a warning to select donors carefully and we would like to suggest a routine thrombophilia screen and general health assessment prior to donation. Whether the administration of low-dose heparin may be necessary should be clarified in further trials.
